Key result
Cell block immunohistochemistry of pulmonary microvascular cytology accurately diagnosed lung adenocarcinoma as the origin of pulmonary tumor thrombotic microangiopathy.
Why the study?
Pulmonary tumor thrombotic microangiopathy is rare but should be considered as a possible diagnosis in patients with cancer.
Case Report (n=1)
Cell-block immunohistochemistry of pulmonary microvascular cytology is a safe and effective diagnostic option for identifying the origin of pulmonary tumor thrombotic microangiopathy.
May support pulmonary microvascular cytology with IHC for identifying PTTM origin; leaves open validation in prospective series.
Pulmonary tumor thrombotic microangiopathy (PTTM) is rare but should be considered as a possible diagnosis in patients with cancer. In this case, PTTM induced by lung cancer was more accurately diagnosed using cell block immunohistochemistry of pulmonary microvascular cytology (PMC) because we could confirm that lung adenocarcinoma was the origin of PTTM by the positive result of TTF-1 for atypical cells in PMC. The PMC procedure was minimally invasive and safer than lung biopsy. We believe that the cell block technique of PMC should be considered as one diagnostic option in PTTM.
No takes yet. Share an insight, caveat, or question.
Yamakawa et al. (2019) conducted a case report in Pulmonary tumor thrombotic microangiopathy (PTTM) associated with lung cancer (n=1). Cell block immunohistochemistry of pulmonary microvascular cytology (PMC) was evaluated on Accurate diagnosis of PTTM origin. Cell block immunohistochemistry of pulmonary microvascular cytology accurately diagnosed lung adenocarcinoma as the origin of pulmonary tumor thrombotic microangiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: